Regulatory Alerts
Keep up-to-date with key announcements and guidance from organisations including NICE, DHSC and MHRA.
Oesophageal cancer treatment recommended
Pembrolizumab recommended in final NICE draft guidance as a first-line treatment for untreated advanced oesophageal and gastro-oesophageal junction cancer.
NICE recommends treatment for hereditary angioedema
New NICE draft guidance means that close to one third of patients with hereditary angioedema in England will be eligible for berotralstat, the first oral treatment for this condition to be made available on the NHS.
Nivolumab recommended for recurrent or metastatic head and neck cancer
NICE has issued draft guidance recommending nivolumab for routine NHS use after platinum-based chemotherapy.
JCVI issues updated advice on COVID-19 booster vaccination
'Decision on booster programme welcome, but primary care will need support', says NHS Confederation.
SMC accepts treatment for colorectal cancer
Pembrolizumab is accepted for restricted use within NHS Scotland.
SMC accepts treatment for severe active rheumatoid arthritis
Filgotinib is accepted for restricted use within NHS Scotland.
SMC accepts treatment for thyroid cancer
Selpercatinib is accepted for use within NHS Scotland on an interim basis subject to ongoing evaluation and future reassessment.